PL354777A1 - Method and compositions for administering taxanes orally to human patients - Google Patents

Method and compositions for administering taxanes orally to human patients

Info

Publication number
PL354777A1
PL354777A1 PL00354777A PL35477700A PL354777A1 PL 354777 A1 PL354777 A1 PL 354777A1 PL 00354777 A PL00354777 A PL 00354777A PL 35477700 A PL35477700 A PL 35477700A PL 354777 A1 PL354777 A1 PL 354777A1
Authority
PL
Poland
Prior art keywords
compositions
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
PL00354777A
Other languages
English (en)
Polish (pl)
Inventor
Samuel Brodor
Kenneth Duchin
Sami Selim
Original Assignee
Baker Norton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of PL354777A1 publication Critical patent/PL354777A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00354777A 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients PL354777A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27

Publications (1)

Publication Number Publication Date
PL354777A1 true PL354777A1 (en) 2004-02-23

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354777A PL354777A1 (en) 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients

Country Status (18)

Country Link
EP (1) EP1225956A1 (de)
JP (1) JP2003512443A (de)
KR (1) KR20030019296A (de)
CN (1) CN1450923A (de)
AU (1) AU1104201A (de)
BR (1) BR0015149A (de)
CA (1) CA2389583A1 (de)
CO (1) CO5251425A1 (de)
CZ (1) CZ20021484A3 (de)
HU (1) HUP0203303A3 (de)
IL (1) IL149360A0 (de)
MX (1) MXPA02004164A (de)
NO (1) NO20022008L (de)
PL (1) PL354777A1 (de)
RU (1) RU2002113659A (de)
SK (1) SK5822002A3 (de)
WO (1) WO2001030448A1 (de)
ZA (1) ZA200203358B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2504268A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane
EP4308114A1 (de) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1-inhibitoren zur behandlung von überempfindlichkeitsreaktionen gegen taxane

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
HUP0003546A3 (en) * 1997-05-27 2002-12-28 Baker Norton Pharma Compositions for administering taxanes orally to human patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN100341485C (zh) * 1998-04-01 2007-10-10 斯凯伊药品加拿大公司 抗癌组合物
CA2684454A1 (en) * 1999-05-21 2000-11-18 American Bioscience, Llc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
NO20022008L (no) 2002-06-19
JP2003512443A (ja) 2003-04-02
HUP0203303A2 (hu) 2003-02-28
WO2001030448A1 (en) 2001-05-03
CA2389583A1 (en) 2001-05-03
CO5251425A1 (es) 2003-02-28
ZA200203358B (en) 2003-04-29
SK5822002A3 (en) 2003-01-09
BR0015149A (pt) 2002-10-29
NO20022008D0 (no) 2002-04-26
RU2002113659A (ru) 2004-01-27
IL149360A0 (en) 2002-11-10
CZ20021484A3 (cs) 2003-12-17
EP1225956A1 (de) 2002-07-31
AU1104201A (en) 2001-05-08
CN1450923A (zh) 2003-10-22
KR20030019296A (ko) 2003-03-06
HUP0203303A3 (en) 2005-01-28
MXPA02004164A (es) 2002-10-17

Similar Documents

Publication Publication Date Title
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0101246A3 (en) Novel galenic formulations of meloxicam for oral administration and process for their preparation
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
EP1227821A4 (de) Therapeutische zusammensetzungen und verfahren zur verwendung davon
HUP0302726A3 (en) Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
HUP0301244A3 (en) Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases
IL132992A0 (en) Method and compositions for administering taxanes orally to human patients
EP1181022A4 (de) Medizinische zusammensetzungen und verfahren zu deren herstellung
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
EG23994A (en) Pharmaceutical compositions for oral and topical administration
EP1210075A4 (de) Zusammenstellungen und methoden zur veränderung des fettgehalts der haut
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0201667A3 (en) Oral form of administration
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
AU784159C (en) Method and compositions for administering taxanes orally to human patients
EP1352652A4 (de) Fettzusammensetzung zur oralen oder enteralen verabreichung und hexacosansäurehemmer
EP1188440A4 (de) Medizinische zusammensetzungen zur oralen verabreichung
AU1621501A (en) Methods and compositions for treatment of disease
HU9801869D0 (en) Pharmaceutical composition for enhancing level of l-carnitin in human patients
AU2003284647A8 (en) Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue
HUP9903735A3 (en) Use of indazolo derivatives for producing pharmaceutical compositions for treatment heart failure
HK1047028A1 (zh) 含有紫杉烷的口服藥物組合物以及使用其的治療方法

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)